Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

  • Blood Cancer Research Partnership

    Blood Cancer Research Partnership group photo - 2016

    Blood Cancer Research Partnership’s (BCRP) mission is to provide innovative clinical trials to patients closer to their home. Far too often, patients diagnosed with cancer do not have access to ground-breaking trials due to lack of proximity to large medical centers.

    About BCRP

    BCRP’s main objective is to bring the novel trials to the patients across the country. We believe the collaboration between community oncologists and Dana-Farber Cancer Institute physicians will accelerate the advancement of and expansion of access to well-designed and innovative clinical trials for blood cancer patients being treated at community sites.


    • Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
    • Leukemia and Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services.
    • LLS Therapy Acceleration Program (TAP), a strategic initiative to speed the development of blood cancer treatments and supportive diagnostics. The Clinical Trials Division of LLS TAP helps patients gain easier access to clinical trial studies in the community and familiar settings.

    Leadership and Investigators

    Rob Soiffer, MD
    CO-PI BCRP; Professor of Medicine Dana-Farber Cancer Institute, Harvard Medical School; Chief, Hematologic Malignancies

    Dr. Robert Soiffer

    Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident.

    He joined DFCI in 1988, after completing a medical oncology fellowship. He is currently chief of the Division of Hematologic Malignancies and co-director of the Adult Stem Cell Transplantation Program. He has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.

    Irene Ghobrial, MD
    CO-PI BCRP; Associate Professor of Medicine Dana-Farber Cancer Institute, Harvard Medical School

    Irene Ghobrial, MD

    Dr. Ghobrial is an Associate Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. She is a physician Scientist who specializes in the field of Multiple Myeloma and Waldenstrom Macroglobulinemia.

    Her research interests are in the area of cell trafficking and cell metastasis in B cell malignancies and specific homing to the bone marrow niches. She is the principal investigator of several clinical trials in Multiple Myeloma and Waldenstrom Macroglobulinemia.

    Matthew Davids, MD
    CO-PI BCRP; Physician at Dana-Farber Cancer Institute, Instructor in Medicine, Harvard Medical School

    Matthew Davids, MD

    Dr. Davids completed his M.D. at the Yale University School of Medicine. He served as an intern and resident in internal medicine at the NewYork-Prebyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in the Dana-Farber Partners CancerCare program.

    He is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies at Dana-Farber, and an Instructor in Medicine at Harvard Medical School. Dr. Davids has an active translational research program in chronic lymphocytic leukemia (CLL), studying mechanisms of treatment resistance and how resistance can be overcome in the laboratory, and developing clinical trials to evaluate these strategies in patients with CLL.

    Farah Daftary
    Director of Clinical Trial Operations at Dana-Farber Cancer Institute

    Farah is the Co-Director of the Clinical Trials Office at Dana-Farber Cancer Institute. She is well versed in clinical research, particularly in hematologic malignancies. Farah oversees the Clinical Research Managers in the Hematologic Malignancies Department.

    Alexandra Savell
    Research Project Manager

    Alexandra is the clinical trial specialist for the Blood Cancer Research Partnership. She has extensive knowledge of hematologic malignancy clinical trial operations, and a background in public health policy and epidemiology from the University of Massachusetts at Amherst.

    Keting Chu, MD, PhD
    LLS VP, Therapy Acceleration Program

    Keting Chu, MD, PhD

    Dr. Chu leads the TAP team for LLS. She is the Co-Founder, President and CEO of DigitAB, Inc., a startup company with a proprietary technology to revolutionize the proteomic research and medical diagnostics fields.

    She received her M.D. in Sun Yat-Sen Medical University in China, Ph.D. in microbiology and immunology at University of California at San Francisco (UCSF), and conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.

    Jun Xu, PhD
    LLS Director, Therapy Acceleration Program

    Jun Xu, PhD

    Dr. Jun Xu is Senior Director for the Therapy Acceleration ProgramTM (TAP) at The Leukemia & Lymphoma Society (LLS). LLS TAP seeks to fund clinical development of therapies that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need. Dr. Xu has personally reviewed over 100 funding requests to select the best ones to be supported by LLS. She also serves as Research Advisory Committee member for a diverse LLS TAP alliance portfolio, mostly innovative immunotherapies. Prior to joining LLS Dr. Xu spent more than 16 years working in health care industry including more than a decade at Pfizer. She has successfully led multiple projects in Oncology and Immunology from target validation to clinical development. Dr. Xu has broad and in-depth experience in drug discovery and development, especially in oncology and inflammation therapeutic areas. Dr. Xu has published in peer reviewed journals including Nature and is the lead inventor for several patents. Dr. Xu received her Ph.D. from the University of California, San Diego and conducted her postdoc research at the California Institute of Technology.

    Community Principal Investigators

    Asad Bashey, MD, PhD
    Blood and Marrow Transplant Group of Georgia

    Asad Bashey, MD, PhD

    Dr. Bashey is board certified in the subspecialties of medical oncology and hematology. He is the clinical research Medical Director for Blood and Marrow Transplant Program at Northside Hospital. For 2013, Dr. Bashey has been selected as a Castle Connolly Top Doctor in the field of Hematology.

    Dr. Bashey's clinical and research interests include novel approaches to allogeneic bone marrow transplantation, strategies for augmentation of the graft-versus-tumor effect after allogeneic transplantation, and stem cell mobilization. He has received major funding from the National Institutes of Health for his clinical research. He currently serves as the Principal Investigator for The Blood and Marrow Transplant Program at Northside Hospital's Core Center status with the Bone Marrow Transplant Clinical Trials Network (BMTCTN).

    Adam Boruchov
    St. Francis Medical Center

    Adam Boruchov

    Dr. Boruchov completed a hematology/oncology fellowship at Memorial Sloan Kettering Cancer (MSKCC) and then joined the MSKCC faculty on the hematology service. He conducted clinical trials and laboratory research with a focus on immune therapies for cancer.

    In 2008 he moved to the Saint Francis/Mount Sinai Regional Cancer Center as an Assistant Professor at UCONN Health Science Center. He recently became the clinical director of the Lea Economos Hematology Center for Clinical Research. Dr. Boruchov’s practice is limited to treating patients with benign and malignant conditions of the bone marrow, including leukemias, lymphomas, multiple myeloma, MDS and myeloproliferative disorders.

    Jeffrey Matous, MD
    Colorado Institute of Blood Cancer

    Jeffrey Matous, MD

    Dr. Matous, specializes in the treatment of blood cancers such as multiple myeloma, amyloidosis, lymphoma and leukemia, as well as in the field of blood and marrow transplantation. Dr. Matous received his medical degree with honors from the University of Washington. He completed his internal medicine residency and chief residency at the University of Colorado Health Sciences Center. He is presently the medical director for the Colorado Blood Cancer Institute as well as a clinical professor of medicine at the University of Colorado Health Sciences Center. He is also on the board of the Leukemia-Lymphoma Society.

    Dr. Matous has a particular interest in medical education and supervises both medical students and internal medicine residents who are interested in the field of hematology/oncology. He has been recognized as an outstanding clinical teacher of the medicine housestaff. He is the lead investigator in clinical trials in the areas of lymphoma, Waldenstrom’s Macroglobulinemia, and multiple myeloma.

    Don Park, MD, PhD
    Director, Hemophilia Clinic, West Michigan Cancer Center & Institute for Blood Disorders

    Don Park, MD, PhD

    Dr. Park has practiced medicine for more than 24 years, including 14 years in academic medicine at Vanderbilt University School of Medicine, where he taught physicians and medical students. During that time, he also served as acting chief and chief of Hematology at the Veterans Administration (VA) Hospital affiliated with the Tennessee Valley Healthcare System in Nashville.

    Dr. Park is board-certified in internal medicine, hematology, and medical oncology. His clinical interests are leukemia, lymphoma, multiple myeloma, hemophilia, anemia, and clotting disorders.

    Jens Rueter, MD
    Medical Director, Translational Research Program, Eastern Maine Medical Center (EMMC)

    Jens Rueter, MD

    Dr. Rueter joined EMMC Cancer Care in 2010, after completing a hematology/oncology fellowship at the Hospital of the University of Pennsylvania and an internal medicine residency at Tulane University School of Medicine in New Orleans. Prior to this, Dr. Rueter obtained his medical degree at the Humboldt University in Berlin, Germany, and worked as a post-graduate scientist in immunology at the Charité, the Medical Faculty of Humboldt University in Berlin. Dr. Rueter has a long-standing interest and expertise in translational cancer research, with a special focus on cancer immunology, chronic lymphocytic leukemia (CLL), and other B-cell malignancies.

    Leyla Shune, MD
    The University of Kansas Medical Center

    Leyla Shune, MD

    Dr. Shune is an assistant professor of Medicine with The University of Kansas Medical Center, specializing in blood and marrow transplantation, cellular medicine, and hematology. Dr. Shune's clinical practice focuses on blood and marrow transplantation, cord blood transplantation, haplotype mismatched allograft transplantation, leukemia, and lymphoma.

    Dr. Shune is a graduate of Istanbul University. She completed her residency in internal medicine and a fellowship in hematology oncology and transplantation at the University of Minnesota. While at Memorial Sloan Kettering Cancer Center in New York, she completed her fellowship in bone marrow transplantation. She is a member of multiple organizations, including the American Society of Hematology, American Society of Bone Marrow Transplantation, and American Society of Clinical Oncology.

    Laura Stampleman, MD
    Pacific Cancer Care

    Laura Stampleman, MD

    Dr. Stampleman completed her undergraduate degree at The City College of the City University in New York, NY. She received her Medical Degree from Albert Einstein College of Medicine in New York, NY. She completed her residency at The Stamford Hospital in Stamford, CT and her Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center in New York, NY.

    Dr. Stampleman is the principal investigator for both Pacific Cancer Care and the ECOG CCOP of Salinas Valley memorial hospital. She served as the Medical Director of the ACOS certified program at Salinas Valley for 6 years and remains active in the cancer program with an emphasis on clinical trial enrollment and survivorship care. Dr. Stampleman lives with her husband in Aromas. They have two children and two grandchildren. In her spare time she enjoys hiking, gardening, baking, cooking and listening to music.

    Eric Wiedower, DO
    West Cancer Center

    Eric Wiedower, DO

    Eric Wiedower, DO, completed his fellowship in Medical Oncology & Hematology at West Cancer Center. During his Fellowship, he served as Chief Fellow — a prestigious honor awarded by West Cancer Center faculty to one of the top performing fellows. He also served as chief resident during his Internal Medicine residency at the University of Kansas, where he demonstrated excellence and leadership among his peers. In addition to a reputation of compassionate clinical care, Wiedower is an award-winning researcher, recognized at some of the world’s premier cancer conferences. He is a member of the American Society of Hematology, as well as the American Society of Clinical Oncology.

    Ira Zackon, MD
    New York Oncology Hematology

    Ira Zackon, MD

    Dr. Zackon is the Director of the New York Oncology Hematology Stem Cell Transplant Program. He completed a professional development program in Autologous Stem Cell Transplantation and Hematologic Malignancies at the Dana-Farber Cancer Institute during 2011-12.

    In addition to further expanding his expertise in this specialized arena, he has enhanced the collaborative relationships with Dana-Farber specialists. Dr. Zackon most values family time with his wife and two children; he enjoys leisure sports and is an active community volunteer.


    Participating Sites

    • Blood and Marrow Transplant Group of Georgia at Northside Hospital is a collaboration between The Blood and Marrow Transplant Group of Georgia (BMTGA) and Northside Hospital. The NSH-BMT Program is one of the largest clinical transplant programs in the United States, serving patients undergoing bone marrow/stem cell transplant therapy and providing primary leukemia treatment. NSH-BMT staff includes nationally recognized physicians, mid-level practitioners, nurses, coordinators, clinical BMT PharmD.’s, a dedicated health psychologist, nutritionists, physical therapists and ancillary specialists.
    • Colorado Blood Cancer Institute (CBCI) is a new program established by the expert physicians who have served Rocky Mountain Blood and Marrow Transplant Program patients for more than 15 years. CBCI was developed to provide state-of-the-art treatment for blood cancers such as leukemia, lymphoma and multiple myeloma. CBCI is a FACT-accredited program for both autologous and allogeneic transplants, performing related and unrelated donor transplants including cord blood transplants. CBCI conducts cutting edge clinical research, testing innovative treatments for patients with blood cancers and bone marrow diseases. Referral to a blood cancer specialist early after diagnosis allows for full evaluation of treatment options and the development of a treatment plan including access to approximately 50 clinical trials. The physicians and staff can discuss research studies to ensure that patients receive the most progressive therapies available.
    • Eastern Maine Medical Center is accredited through the American College of Surgeons – Commission on Cancer with commendation as Maine's only Comprehensive Community Cancer Program recognized for outstanding achievement, and is proud to offer many national clinical trials locally. EMMC received the 2014 American College of Surgeons – Commission on Cancer Outstanding Achievement Award.
    • The University of Kansas Cancer Center is an NCI-designated cancer center and a U.S. News & World Report Top 50 cancer program. Kansas's largest, most experienced blood and marrow transplant (BMT) program has performed more than 3,000 transplants, averaging 300 per year. Patients have access to the widest range of treatment options, including clinical trials. The Center's BMT program provides autologous, allogeneic, haploidentical, and cord blood transplantation. A multidisciplinary team, including nurse navigators, provides personalized care in the 49-bed inpatient unit and outpatient Cancer and Therapeutic Blood Treatment Center. The Center's advances in half-matched donor transplant (haploidentical) allows for a broader range of donors, increased donor matches, shorter transplant wait times, and, ultimately, more saved lives. The Cancer Center is also part of the ACS Commission on Cancer, FACT, NMDP, BMT-CTN Core Center, the Myeloproliferative Disorders Research Consortium, and SWOG, and is an ANCC Magnet hospital.
    • New York Oncology Hematology (NYOH) is the leading provider of community-based cancer care services in New York State’s capital region. The NYOH medical staff includes 35 board certified physicians who specialize in the care of patients with cancer (medical oncology and radiation oncology) and blood-related disorders (hematology). With a patient care team of more than 300 oncology certified nurses, pharmacists, laboratory technologists, radiation therapists and support personnel and seven, easy-access locations, NYOH is the renowned cancer care provider of choice for thousands of area residents. NYOH physicians include 5 dedicated Hematologists mostly centered at our office at Albany Medical Center, where it also provides an outpatient autologous bone marrow stem cell transplantation service.
    • Pacific Cancer Care has been a leading provider of oncology and hematology services for over 30 years. Previously known as Monterey Bay Oncology and Los Palos Oncology and Hematology, the group has grown to become the major provider of oncology and hematology services in Central California. PCC is a place where experienced physicians care for their patients with the support of highly skilled nurses and a dedicated staff. Equipped with all the latest advances, the PCC team offers patients a complete, comprehensive program across the continuum of care. PCC patients receive the best possible care, which is both personalized, comprehensive and advanced, in a caring environment that is close to home.
    • The Saint Francis/Mount Sinai Regional Cancer Center is one of the region’s leading cancer treatment centers, located on the campus of St. Francis Hospital, a 600-bed community teaching hospital in Hartford, CT. The 45,000 square foot Cancer Center opened in 1993, and houses radiation oncology, medical oncology, and hematology, along with a broad network of support services. Within the cancer center, the Lea Economos Hematology Center for Clinical Research includes 5 physicians whose clinical focus is patients with hematologic malignancies, with access to cutting edge technology and clinical trials sponsored by NCI cooperative groups, pharmaceutical companies, and academic partners. This care is provided by specialized nurses, midlevel providers, physicians and clinical navigators in a patient- and family-focused environment.
    • West Cancer Center is a community-based oncology practice located in Memphis, TN. For over 34 years, the dedicated physicians and staff at West Cancer Center have been providing the highest quality care and cutting edge therapies for their patients located in the Midsouth. Our multidisciplinary physician group is comprised of 35 specialists in medical oncology, hematology, gynecologic oncology, breast surgery, radiation oncology, endocrinology, diagnostic and interventional radiology, as well as pain and palliative care. The clinical research program has successfully conducted over 350 phase I – III clinical trials.
    • West Michigan Cancer Center and Institute for Blood Disorders (WMCC) was founded in 1994 as a not-for-profit collaboration between Borgess Health and Bronson Methodist Hospital. WMCC offers comprehensive, multidisciplinary, integrative cancer treatment. WMCC is affiliated with the Cancer Research Consortium of West Michigan (CRCWM), a member of the National Cancer Institute Clinical Oncology Research Program (NCORP). It was one of the nation's first oncology practices to be recognized by the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO). The Center is accredited by the American College of Radiation Oncology (ACRO), the American College of Radiology Imaging Network (ACRIN), and the National Accreditation Program for Breast Centers (NAPBC).

    Clinical Trials

    Open to Enrollment

    CTEP: 9204/DFCI 12-537: A Phase I/Ib Study of Ipilimumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (NCT 01822509)

    Participating Sites:

    DF/HCC 14-296: A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia (NCT 02251548)

    Participating Sites:

    DF/HCC 14-396: A Multicenter Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies (NCT 02268851)

    Participating Sites:

    DF/HCC 14-338: Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma (NCT 02279394)

    Participating Sites:

    DF/HCC 14-508: A Phase II study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma (NCT 02441686)

    Participating Sites:

    DF/HCC 14-174: A Prospective, Longitudinal, Observational Study in Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome

    Participating Sites:


    Contact BCRP

    For more information, contact:

    Alexandra Savell
    Phone: 617-632-3539

  •   Email
  •   Print
  •   Share